Vestcor Inc Cuts Stock Position in Medpace Holdings, Inc. $MEDP

Vestcor Inc trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 36.4% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,671 shares of the company’s stock after selling 1,528 shares during the period. Vestcor Inc’s holdings in Medpace were worth $1,373,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Schroder Investment Management Group purchased a new stake in Medpace in the 3rd quarter worth $627,000. Inceptionr LLC lifted its holdings in Medpace by 3.0% during the third quarter. Inceptionr LLC now owns 3,136 shares of the company’s stock valued at $1,612,000 after purchasing an additional 90 shares in the last quarter. Diversify Advisory Services LLC lifted its holdings in Medpace by 21.5% during the third quarter. Diversify Advisory Services LLC now owns 3,181 shares of the company’s stock valued at $1,636,000 after purchasing an additional 563 shares in the last quarter. Vinva Investment Management Ltd acquired a new stake in shares of Medpace in the third quarter valued at about $325,000. Finally, Meiji Yasuda Asset Management Co Ltd. acquired a new stake in shares of Medpace in the third quarter valued at about $265,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 2.3%

Shares of NASDAQ MEDP opened at $477.72 on Thursday. The firm has a 50-day simple moving average of $528.39 and a 200-day simple moving average of $539.24. The stock has a market capitalization of $13.56 billion, a price-to-earnings ratio of 31.22, a price-to-earnings-growth ratio of 2.24 and a beta of 1.44. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same period in the previous year, the business posted $3.67 earnings per share. Medpace’s quarterly revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on MEDP shares. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and reduced their price target for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Royal Bank Of Canada began coverage on Medpace in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 price objective on the stock. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a research note on Friday, February 13th. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Finally, Truist Financial decreased their target price on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Five analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $486.67.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.